Scott L. Burrows - 15 Jan 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
15 Jan 2025
Net transactions value
$0
Form type
4
Filing time
17 Jan 2025, 16:36:48 UTC
Previous filing
05 Sep 2024
Next filing
03 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +95,500 $0.000000 95,500 15 Jan 2025 Common Stock 95,500 $21.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.